Newstral
Article
jdsupra.com on 2017-08-28 23:29
FDA Approves Boehringer Ingelheim’s Adalimumab Biosimilar
Related news
- FDA Approves Coherus’ Adalimumab Biosimilar YUSIMRY™jdsupra.com
- FDA Approves Pfizer’s Adalimumab Biosimilar ABRILADAjdsupra.com
- New BPCIA Litigaton: AbbVie Sues Boehringer Ingelheim Regarding Proposed Biosimilar to Humira (adalimumab)jdsupra.com
- EC Approves Amgen’s Biosimilar Adalimumabjdsupra.com
- Sandoz Obtains FDA Approval for Adalimumab Biosimilarjdsupra.com
- FDA Approves 25th Biosimilarjdsupra.com
- FDA Approves First Avastin Biosimilarjdsupra.com
- FDA Approves Third Biosimilar Productjdsupra.com
- Teva and Alvotech’s Adalimumab Biosimilar Receives Interchangeable Status at FDAjdsupra.com
- Celltrion Files IND with FDA for Adalimumab Biosimilarjdsupra.com
- FDA Approves First Rituximab Biosimilarjdsupra.com
- FDA Approves Rheumatoid Arthritis Biosimilarwsj.com
- FDA Approves First Biosimilar Drugwsj.com
- FDA Approves Sandoz’s Biosimilar Pegfilgrastimjdsupra.com
- FDA Approves Sandoz Filgrastim Biosimilarjdsupra.com
- FDA Approves Lantus® Interchangeable Biosimilarjdsupra.com
- FDA Approves Celltrion’s Trastuzumab Biosimilarjdsupra.com
- FDA Approves Pfizer’s EPO Biosimilarjdsupra.com
- FDA Approves Another Interchangeable Biosimilarjdsupra.com
- FDA Approves Mylan’s Biosimilar of HUMIRA (Adalimumab)jdsupra.com